Peyvand Biglari
Pasteur Institute of Iran
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Peyvand Biglari.
Molecular Biology Reports | 2013
Firouzeh Farahtaj; Fatemeh Zandi; Vahid Khalaj; Peyvand Biglari; Ahmad Fayaz; Behrouz Vaziri
In order to extend the knowledge of rabies pathogenesis, a two-dimensional electrophoresis/mass spectrometry based postmortem comparative proteomics analysis was carried out on human brain samples. Alteration in expression profile of several proteins was detected. Proteins related to cytoskeleton, metabolism, proteasome and immune regulatory systems showed the most changes in expression levels. Among these groups, the cytoskeleton related proteins (dynein light chain, β-centractin, tubulin alpha-1C chain and destrin) and metabolism associated proteins (fatty acid-binding protein, macrophage migration inhibitory factor, glutamine synthetase and alpha enolase) were the main altered proteins. These alterations may be considered as an evidence of disturbances in neuronal key processes including axonal transport, synaptic activity, signaling and metabolic pathways in rabies virus infected human brain.
Vaccine | 2011
Ahmad Fayaz; S. Simani; Alireza Janani; Firouzeh Farahtaj; Peyvand Biglari; Nader Howeizi; Nasser Eslami
In 1975-1976 forty-five persons severely bitten by rabid wolves and dogs in Iran were treated successfully against rabies with HDCV. In this study contact was made with 26 of 45 above persons, 32 years after their initial treatment and all had rabies neutralizing antibody ranging from 0.3 to 2.69 IU/ml of serum. Of the 26 persons, 17 had received a booster dose of HDCV, 28 years ago and the remaining 9 persons, who had not received any booster since the initial treatment, were given one booster dose of HDCV. All 9 of these patients developed an anamnestic response after their booster inoculation. This study confirms the persistence of rabies neutralizing antibody in persons that received post-exposure vaccination with HDCV, 32 years previously. Furthermore, a single booster inoculation with HDCV resulted in anamnestic response in all individuals.
Tropical Doctor | 2014
Firouzeh Farahtaj; Ahmad Fayaz; Nader Howaizi; Peyvand Biglari; Alirez Gholami
Background Like most Asian and African countries, Iran is highly endemic for rabies, which is a preventable disease with the timely utilisation of post-exposure prophylaxis (PEP). With the availability of affordable vaccination in Iran, there are still several rabies deaths which are assumed misdiagnosed or received ineffective PEP. Methods We reviewed the files of 16 human rabies deaths, consisting of two groups: 1, ineffective treatment; and 2, erroneous PEP. Results Most of the studied cases were male and were from rural areas. Stray dogs were found to be the common biting animal (68.75%). Of the patients, 10/16 (62.5%) who had injuries on their head and/or face demonstrated shorter incubation periods. The incubation period was longer in a 4-year-old boy who sustained injuries in his abdomen and back. All the patients in group 1 received four doses of vaccine and administration of human rabies immune globulin (HRIG), and death occurred with the mean of 49 days after the bite. This mean was 27 days in three patients in group 2, who received vaccine without administration of HRIG. Conclusion In a total of 1,188,579 cases of PEP given in Iran during: 2002–2011, it is not known whether all PEPs were correctly administered by World Health Organization standards. Extending rabies awareness programmes and timely PEP education in the community in accordance with the implementation of rabies control measures might lead to a decrease in these unfortunate scenarios and heavy financial burden of vaccination required due to the prevalence of rabies.
Journal of Liposome Research | 2017
Yahya Mohammadzadeh; Shima Gholami; Narges Rasouli; Sahar Sarrafzadeh; Nasim Sadat Seyed Tabib; Mohammad Hasan Samiee Aref; Asghar Abdoli; Peyvand Biglari; Fatemeh Fotouhi; Behrokh Farahmand; Masoumeh Tavassoti Kheiri; Abbas Jamali
Abstract Insect-derived cell lines are used extensively to produce recombinant proteins because they are capable of performing a range of post-translational modifications. Due to their significance in biotechnological applications, various methods have been developed to transfect them. In this study, we introduce a virosome constructed from vesicular stomatitis virus (VSV) as a new delivery system for sf9 cells. We labeled these VSV virosomes by fluorescent probe Rhodamine B chloride (R18). By fluorescence microscope observation and conducting a fusion assay, we confirmed the uptake of VSV virosomes via endocytosis by sf9 cells and their fusion with the endosomal membrane. Moreover, we incubated cationic VSV virosomes with a GFP-expressing bacmid and transfected sf9 cells, after 24 h some cells expressed GFP indicating the ability of VSV virosomes to deliver heterologous DNA to these cells. This is the first report of a virosome-based delivery system introduced for an insect cell line.
Biotechnology Letters | 2016
Yahya Mohammadzadeh; Narges Rasouli; Mohammad Hasan Samiee Aref; Nasim Sadat Seyed Tabib; Asghar Abdoli; Peyvand Biglari; Maryam Saleh; Mansoureh Tabatabaeian; Masoumeh Tavassoti Kheiri; Abbas Jamali
ObjectivesTo enhance the efficiency of influenza virosome-mediated gene delivery by engineering this virosome.ResultsA novel chimeric influenza virosome was constructed containing the glycoprotein of Vesicular stomatitis virus (VSV-G), along with its own hemagglutinin protein. To optimize the transfection efficiency of both chimeric and influenza cationic virosomes, HEK cells were transfected with plasmid DNA and virosomes and the transfection efficiency was assessed by FACS analysis. The chimeric virosome was significantly more efficient in mediating transfection for all amounts of DNA and virosomes compared to the influenza virosome.ConclusionsChimeric influenza virosome, including VSV-G, is superior to the conventional influenza virosome for gene delivery.
Developments in biologicals | 2008
A R Janani; Ahmad Fayaz; S. Simani; Firouzeh Farahtaj; N. Eslami; Nader Howaizi; Peyvand Biglari; M. Sabetghadam
Journal of Babol University of Medical Sciences | 2009
Ahmad Fayaz; S. Simani; A R Janani; Firouzeh Farahtaj; Esfandyari Behzad; Eslami Naser; N Houvizi; Peyvand Biglari; V Falahian; M Sabet Ghadam
Archives of Virology | 2018
Sanaz Baghban Rahimi; Alireza Mohebbi; Gelareh Vakilzadeh; Peyvand Biglari; Soodeh Razeghi Jahromi; Seyed Reza Mohebi; Sadegh Shirian; Ali Gorji; Amir Ghaemi
Iranian Journal of Virology | 2008
Ahmad Fayaz; Firouzeh Farahtaj; Eslami Naser; N Hoveyzi; Peyvand Biglari; A R Janani; S. Simani
publisher | None
author